Ivan Van Riet

Prof. Ivan Van Riet

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in World Journal of Stem Cells
Verified
Journal Article
Open access
ABAnn De Becker
Ann De Becker
IRIvan Van Riet
Ivan Van Riet
Homing and migration of mesenchymal stromal cells: How to improve the efficacy of cell therapy?

1 July 2016 in Cancer Letters
Verified
Journal Article
Closed access
KVKim De Veirman
Kim De Veirman
JWJinheng Wang
Jinheng Wang
SXSong Xu
Song Xu
XLXavier Leleu
Xavier Leleu
EHEddy Himpe
Eddy Himpe
IRIvan Van Riet
Ivan Van Riet

18 January 2012 in Stem Cells
Verified
Journal Article
Open access
PDF file
SXSong Xu
Song Xu
Eline MenuEline Menu
Eline Menu
ABAnn De Becker
Ann De Becker
BCBen Van Camp
Ben Van Camp
KVKarin Vanderkerken
Karin Vanderkerken
IRIvan Van Riet
Ivan Van Riet
Multiple myeloma (MM) is a malignancy of terminally differentiated plasma cells that are predominantly localized in the bone marrow (BM). Mesenchymal stromal cells (MSCs) give rise to most BM stromal cells that interact with MM cells. However, the direct involvement of MSCs in the pathophysiology of MM has not been well addressed. In this study, in vitro and in vivo migration assays revealed that MSCs have tropism toward MM cells, and CCL25 was identified as a major MM cell-produced chemoattractant for MSCs. By coculture experiments, we found that MSCs favor the proliferation of stroma-dependent MM cells through soluble factors and cell to cell contact, which was confirmed by intrafemoral coengraftment experiments. We also demonstrated that MSCs protected MM cells against spontaneous and Bortezomib-induced apoptosis. The tumor-promoting effect of MSCs correlated with their capacity to enhance AKT and ERK activities in MM cells, accompanied with increased expression of CyclinD2, CDK4, and Bcl-XL and decreased cleaved caspase-3 and poly(ADP-ribose) polymerase expression. In turn, MM cells upregulated interleukin-6 (IL-6), IL-10, insulin growth factor-1, vascular endothelial growth factor, and dickkopf homolog 1 expression in MSCs. Finally, infusion of in vitro-expanded murine MSCs in 5T33MM mice resulted in a significantly shorter survival. MSC infusion is a promising way to support hematopoietic recovery and to control graft versus host disease in patients after allogeneic hematopoietic stem cell transplantation. However, our data suggest that MSC-based cytotherapy has a potential risk for MM disease progression or relapse and should be considered with caution in MM patients.Disclosure of potential conflicts of interest is found at the end of this article.

22 February 2018 in Leukemia
Verified
Journal Article
Open access
PDF file
SXSong Xu
Song Xu
KVKim De Veirman
Kim De Veirman
ABAnn De Becker
Ann De Becker
KVKarin Vanderkerken
Karin Vanderkerken
IRIvan Van Riet
Ivan Van Riet
Multiple myeloma (MM) is a malignant plasma cell (PC) disorder, characterized by a complex interactive network of tumour cells and the bone marrow (BM) stromal microenvironment, contributing to MM cell survival, proliferation and chemoresistance. Mesenchymal stem cells (MSCs) represent the predominant stem cell population of the bone marrow stroma, capable of differentiating into multiple cell lineages, including fibroblasts, adipocytes, chondrocytes and osteoblasts. MSCs can migrate towards primary tumours and metastatic sites, implying that these cells might modulate tumour growth and metastasis. However, this issue remains controversial and is not well understood. Interestingly, several recent studies have shown functional abnormalities of MM patient-derived MSCs indicating that MSCs are not just by-standers in the BM microenvironment but rather active players in the pathophysiology of this disease. It appears that the complex interaction of MSCs and MM cells is critical for MM development and disease outcome. This review will focus on the current understanding of the biological role of MSCs in MM as well as the potential utility of MSC-based therapies in this malignancy.

19 October 2007 in Clinical & Experimental Metastasis
Verified
Journal Article
Closed access
PDF file
IBIsabelle Vande Broek
Isabelle Vande Broek
KVKarin Vanderkerken
Karin Vanderkerken
BCBenjamin Van Camp
Benjamin Van Camp
IRIvan Van Riet
Ivan Van Riet

27 June 2014 in Cancers
Verified
Journal Article
Open access
PDF file
KVKim De Veirman
Kim De Veirman
LRLuigia Rao
Luigia Rao
EBElke De Bruyne
Elke De Bruyne
Eline MenuEline Menu
Eline Menu
EVEls Van Valckenborgh
Els Van Valckenborgh
KVKarin Vanderkerken
Karin Vanderkerken
Cancer associated fibroblasts (CAFs) comprise a heterogeneous population that resides within the tumor microenvironment. They actively participate in tumor growth and metastasis by production of cytokines and chemokines, and the release of pro-inflammatory and pro-angiogenic factors, creating a more supportive microenvironment. The aim of the current review is to summarize the origin and characteristics of CAFs, and to describe the role of CAFs in tumor progression and metastasis. Furthermore, we focus on the presence of CAFs in hypoxic conditions in relation to multiple myeloma disease.